CY1111467T1 - Μορια ανθρωπινου αντισωματος για την il-13 - Google Patents

Μορια ανθρωπινου αντισωματος για την il-13

Info

Publication number
CY1111467T1
CY1111467T1 CY20111100456T CY111100456T CY1111467T1 CY 1111467 T1 CY1111467 T1 CY 1111467T1 CY 20111100456 T CY20111100456 T CY 20111100456T CY 111100456 T CY111100456 T CY 111100456T CY 1111467 T1 CY1111467 T1 CY 1111467T1
Authority
CY
Cyprus
Prior art keywords
motorcycle
ill
human response
antibody molecules
hodgkin
Prior art date
Application number
CY20111100456T
Other languages
Greek (el)
English (en)
Inventor
Phillip David Monk
Lutz Jermutus
Ralph Raymond Minter
Celia Patricia Shorrock
Original Assignee
Medimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0407315.1A external-priority patent/GB0407315D0/en
Application filed by Medimmune Limited filed Critical Medimmune Limited
Publication of CY1111467T1 publication Critical patent/CY1111467T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY20111100456T 2003-07-15 2011-05-16 Μορια ανθρωπινου αντισωματος για την il-13 CY1111467T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48751203P 2003-07-15 2003-07-15
US55821604P 2004-03-31 2004-03-31
GBGB0407315.1A GB0407315D0 (en) 2003-07-15 2004-03-31 Human antibody molecules
US57379104P 2004-05-24 2004-05-24
EP04743400A EP1646656B1 (en) 2003-07-15 2004-07-15 Human antibody molecules for il-13

Publications (1)

Publication Number Publication Date
CY1111467T1 true CY1111467T1 (el) 2015-08-05

Family

ID=44535047

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100456T CY1111467T1 (el) 2003-07-15 2011-05-16 Μορια ανθρωπινου αντισωματος για την il-13

Country Status (8)

Country Link
JP (3) JP5519567B2 (enExample)
KR (1) KR101073590B1 (enExample)
AU (1) AU2011200308B2 (enExample)
CY (1) CY1111467T1 (enExample)
HK (1) HK1216427A1 (enExample)
MX (1) MXPA06000258A (enExample)
NO (2) NO338853B1 (enExample)
RU (1) RU2009148270A (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016027797A2 (pt) * 2014-06-18 2017-10-31 Medimmune Llc métodos e meios de cultura de células compreendendo n-acetilcisteína

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656947A1 (en) * 1992-08-21 1995-06-14 Schering Corporation Human interleukin-13
JP2005512522A (ja) * 2001-10-26 2005-05-12 セントカー・インコーポレーテツド Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用
US20030235555A1 (en) * 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
JP4723810B2 (ja) * 2001-12-03 2011-07-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド ハイブリッド抗体
JP2006501249A (ja) * 2002-08-30 2006-01-12 グラクソ　グループ　リミテッド ワクチン
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
MXPA06000258A (es) 2006-07-03
HK1155185A1 (en) 2012-05-11
NO342727B1 (no) 2018-07-30
JP5922686B2 (ja) 2016-05-24
NO20060730L (no) 2006-04-10
AU2011200308A1 (en) 2011-02-17
JP2016047843A (ja) 2016-04-07
KR101073590B1 (ko) 2011-10-14
JP2011147454A (ja) 2011-08-04
NO20160707A1 (no) 2016-04-27
JP5519567B2 (ja) 2014-06-11
AU2011200308B2 (en) 2011-07-28
HK1216427A1 (zh) 2016-11-11
JP2014101372A (ja) 2014-06-05
KR20060054312A (ko) 2006-05-22
NO338853B1 (no) 2016-10-24
HK1097853A1 (en) 2007-07-06
RU2009148270A (ru) 2011-06-27

Similar Documents

Publication Publication Date Title
MY144906A (en) Human antibodies against il13 and therapeutic uses
WO2005007699A3 (en) Human antibody molecules for il-13
CY1120874T1 (el) Συνθεση αντισωματος ιντερλευκινης-13
TNSN08333A1 (en) Thymic stromal lymphopoietin (tslp) antibodies and uses thereof
CY1120887T1 (el) Αντισωματα που προσδενουν il-4 και/ή il-13 και οι χρησεις τους
NO20054223L (no) Antistoffmolekyler som har spesifisitet for human IL-1beta
DK1814590T4 (da) Behandling af obesitet og beslægtede sygdomme.
MX2009010765A (es) Anticuerpos anti-ige.
ATE478670T1 (de) Rezeptor-selektive cannabimimetische aminoalkylindole
DK1765322T3 (da) Retinal-derivater og fremgangsmåder til anvendelse deraf i behandlingen af synsforstyrrelser
CY2022028I2 (el) Εξανθρωπισμενα αντισωματα αντι-cd19 και οι χρησεις τους στην θεραπεια ογκων, μεταμοσχευσης και ασθενειων αυτο-ανοσιας
DK1593387T3 (da) Sammensætninger for behandling af uhæmmede interpersonelle og adfærdsmæssige forstyrrelser
EP1626729A4 (en) COMPOSITIONS AND METHODS OF SYMPTOMATIC RELIEF
ATE454148T1 (de) Acylierte piperidinderivative als melanocortin-4- rezeptoragonisten
TNSN08175A1 (en) Human antibodies against il-13 and therapeutic uses
EP1765331A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF LUNG DISEASES
NO20060730L (no) Humane antistoffmolekyler mot IL-13
ATE498010T1 (de) Natürliche igm-antikörper und inhibitoren davon
BRPI0412243A (pt) uso de cd164 solúvel em distúrbios inflamatórios e/ou autoimunes
Khaniyan et al. Understanding exercise behavior among Tehran adolescent girls according
Habibi et al. Effectiveness of dialectical behavior therapy in improving symptoms of patients with dysthymic disorder
TH98075B (th) แอนตี้-tslp แอนตี้บอดี้
Protogerou et al. Evaluation of cognitive-analytic therapy (CAT) outcome in patients with obsessive-compulsive personality disorder
Barthelat 5 The Modeling of Time Dependent Mechanical Properties of Cervine Enamel
BRPI0512874A (pt) composições e métodos para o tratamento de distúrbios inflamatórios